Journal: Blood Cancer Journal

Article Title: A superantigen-based MHC class II-targeted cancer immunotherapy for the treatment of acute myeloid leukemia

doi: 10.1038/s41408-025-01391-w

Figure Lengend Snippet: A Flow cytometry of various AML cell lines showing CD33 cell surface expression with median fluorescence intensity (MFI) quantification. Significance was determined by Mann-Whitney test, ** P < 0.01. B Western blot for anti-6X His tagged recombinant proteins. C ELISA for M2T-CD33 binding to various MHCII alleles, including human, mouse, and dog. IgG1 Fc Knob-in-Hole as a control for MHCII alleles constructed with IgG1 Fc stalk. BSA as negative control. D Flow cytometry of Daudi and Jurkat cells showing TCR and MHCII (HLA-DR) expression, M2T-CD33 binding, and M2T-CD33 double mutant (DM) binding. E Flow cytometry of human PBMCs (healthy donor #1) gating on CD3 or CD19 and then comparing binding of CD33 vs. M2T-CD33. F Flow cytometry of mouse splenocytes gating on CD3 or CD19 and then comparing binding of CD33 vs. M2T-CD33.

Article Snippet: His-Tag Rabbit mAb AF488 (Cat #14930S), Anti-Human CD3 PE (Cat #46233S), and Rat IgG2b Isotype Control PE (Cat #27426S) were purchased from Cell Signaling Technology (Danvers, MA, USA).

Techniques: Flow Cytometry, Expressing, Fluorescence, MANN-WHITNEY, Western Blot, Recombinant, Enzyme-linked Immunosorbent Assay, Binding Assay, Control, Construct, Negative Control, Mutagenesis